TORNTPHARM Q2 FY27 Earnings Call: Rs. 450 Cr Cost Synergies Fast-Tracked, H2 Margin Uplift Signalled

TORNTPHARM held its Q2 FY27 earnings call on October 23, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Merger-Driven Headline Growth; Underlying Base Strong

• Rs.4,979 Cr consolidated revenue, +51% YoY — Q2 FY 2026-2027 growth inflated by the JB merger (effective 8 July 2026); operating EBITDA of Rs.1,666 Cr (+54%) at a 33.5% margin.
• Torrent-based business grew 18% — base India up 20% (vs IPM 12% per PharmaTrac), Brazil up 38%, US generics up 24%, Germany down 7%.
• JB underlying revenues of Rs.1,086 Cr, largely flat YoY — transient integration impact as guided; JB India branded grew 7% while international declined 7%.
• R&D spend rose to 4.2% of revenue — up from 3.5% in Q1 FY 2026-2027; management expects R&D not to exceed 4-4.5% of revenues even in FY 2027-2028.
• Net debt-to-EBITDA at 1.8x — as of Q2 FY 2026-2027.

Cost Synergies Ahead of Plan; Revenue Synergies a FY28 Story

• Rs.450 Cr cost synergy target maintained — delivery accelerated from the original 3 years to 2 years, i.e., by FY 2027-2028; about half is already reflected in FY 2026-2027 margins per CFO Sudhir Menon.
• JB EBITDA margin improved sequentially to 33.5% — from 33.8% in Q1 FY 2026-2027; field force/divisional merger savings were the biggest driver, procurement a smaller contributor.
• International disruption was broad-based — software/accounting integration, merger and process changes caused postponed deliveries; management stressed these were back-office, not customer-facing, and one-time in nature. A quality issue on one US product led to a recall, excluded from the general disruption characterization.
• India revenue synergies expected in FY 2027-2028 — cross-selling, new territories and adding JB brands to Torrent divisions (typically a 6-12 month process per brand); international revenue synergies take 2-3 years, i.e., through roughly FY 2029-2030.
• JB India margin convergence affirmed — management (Aman) agreed JB India profitability should become very similar to Torrent India over the next two-three quarters (Q3 FY 2026-2027 through Q1 FY 2027-2028).
• Rs.950-960 Cr second tranche due December 2026 — pending payment under the JB Chem–Novartis ophthalmology deal; management sees no risk to the deal despite changes at Novartis India.

Base India Outperforms IPM; Semaglutide Franchise Scaling

• India base business grew 20% vs IPM 12% — Rs.2,181 Cr in Q2 FY 2026-2027, driven by elevated IPM growth, new launches, and volume acceleration from field force expansion.
• Semaglutide share at 32% — oral and injectable combined (PharmaTrac), with more than 90% share within generic players in the oral segment; supplies fully restored by September 2026 after a ~2-month injectable supply gap.
• Management concurred with an analyst scenario of ~25% semaglutide market growth in FY 2027-2028 — taking the market to ~Rs.1,000 Cr; a Rs.2,000-2,500 Cr market over the next 3-5 years is "not out of range," though it is too early to size 4-5 years out.
• IPM growth running at 12% in FY 2026-2027 — management expects this to sustain for the rest of FY 2026-2027 but views it as potentially a one-off; FY 2027-2028 growth may drop 1-2%, with a minimum of 10% expected and sub-10% "not looking likely at this stage."
• Curatio grew 34% in Q2 and H1 FY 2026-2027 — now 7-8% of base India business (ex-JV), up from 4-5% at acquisition; high growth sustainable for at least a couple of years, though ~30% growth is difficult to sustain beyond 3-5 years.
• Combined India field force at 9,100 MRs — to be maintained through end of FY 2026-2027; potentially ~500 additional MRs needed in the base business, with FY 2027-2028 headcount possibly 9,500-9,600 (review planned in a couple of months).

Brazil Strong, US Growing on Launches, Germany Under Pressure

• Brazil grew 21% YoY in constant currency — BRL 236 Mn in Q2 FY 2026-2027; per IQA data the Brazil market grew 5.7% while Torrent grew 26%; Q2 growth of 20% split roughly one-third each from price, volume, and new launches.
• 53 molecules under ANVISA review in Brazil — approvals expected over the next 3 years; management guided growth "at least superior to 10%, closer to 15%" in coming years (period unspecified). Constraints: ANVISA timelines of at least 2 years, entrenched local competitors, and price competition that has become much more aggressive over the last 2-3 years.
• US delivered 13% CC growth — $44 Mn in Q2 FY 2026-2027, driven by new launches achieving or exceeding target share; base business is flat with price and volume neutralizing each other.
• US filings at 9-10 for FY 2026-2027 — 4 filed year-to-date with 4-5 more expected, higher than several previous years, cited as grounds for "positive optimism." Management would not commit to current US growth persisting; new entrants face 3-4 retail customers controlling 90% of the market, and competitor counts at launch are uncertain.
• Germany declined 13% CC ($26 Mn) — hit by loss of high-value tenders and third-party supplier disruption; best case is a slight decline over coming quarters with stability after ~3-4 quarters.
• ROW growing high single digit to double digit — Philippines, Mexico, Russia, South Africa; conservative growth guidance of 6-9% (period unspecified), excluding JB total.
• GLP launch in Brazil expected within 6-9 months — a local very large player launched a true generic ~3 months ago, which has accelerated market growth; Torrent optimistically expects its own launch in the next 6-9 months.

H2 Margin Improvement Signalled; FY28 Guidance Deferred

• Combined EBITDA margin at 33.5% in Q2 FY 2026-2027 — CFO Sudhir Menon "definitely" feels H2 FY 2026-2027 EBITDA margin should be a little higher than 33.5%, though no specific number was guided.
• JB margin improvement run-rate may continue for two-three quarters — Q3 FY 2026-2027 through Q1 FY 2027-2028; no exact quantum provided. CFO declined geography-wise EBITDA disclosure, citing company policy.
• No FY28 guidance provided — management will wait for the full-year FY 2026-2027 base and expects to issue guidance in Q1 FY 2027-2028.
• Further cost synergy upside commentary deferred — management will comment by Q1/Q2 FY 2027-2028 only if a more concrete basis emerges; premature to assume upside versus the Rs.450 Cr number.
• H2 FY 2026-2027 priorities — improve market share in focused therapies, lift field force productivity in expanded divisions, and continue scaling Curatio; JB India branded growth in H2 FY 2026-2027 expected perhaps higher than H1's 10%, with total JB growth recovering to double digit.